Gilead (GILD) files Form 13F: $1.28B in holdings

Gilead Sciences filed a Form 13F reporting its institutional holdings as manager.

Rhea-AI Filing Summary

Gilead Sciences filed a Form 13F reporting its institutional holdings as manager. The filing lists 14 holdings with a total reported market value of $1,280,204,668. The report is signed by Andrew D. Dickinson, Executive Vice President and Chief Financial Officer, dated 08-14-2025.

Insights

Institutional Holdings Analyst

Routine quarterly disclosure of holdings with a $1.28B portfolio value.

The report lists 14 Form 13F entries and a total market value of $1,280,204,668, indicating the aggregate public equity positions under Gilead Sciences' reporting manager role. This is a standard regulatory snapshot of holdings at the reporting date.

Timing and transaction details are not provided here; subsequent 13F tables would show individual security names, share counts, and values for more granular analysis.

Compliance & Reporting Specialist

Filing appears procedural and properly executed by the CFO.

The cover indicates one other included manager, Gilead Therapeutics A1 Unlimited Co, and the Form 13F Information Table Entry Total of 14 positions. The signature block shows authorization by Andrew D. Dickinson on 08-14-2025.

This filing is a routine regulatory disclosure; any investor-focused implications depend on the detailed holdings table not included in the provided excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does GILD's Form 13F filing report?

It reports the manager's public equity holdings and totals. The filing lists 14 holdings with a combined market value of $1,280,204,668, signed by the CFO on 08-14-2025.

How many holdings did Gilead report in this 13F for GILD?

The filing lists fourteen reported positions. The Form 13F Information Table Entry Total is 14, and the aggregate market value for those entries is shown as $1,280,204,668.

Who certified the Form 13F for Gilead Sciences (GILD)?

The report was signed by Andrew D. Dickinson, CFO. Signature block identifies him as Executive Vice President and Chief Financial Officer, dated 08-14-2025 on behalf of the reporting manager.

Does this excerpt show the individual securities GILD holds?

No; the provided excerpt shows summary totals only. The cover and summary pages list 14 entries and total value $1,280,204,668; the detailed 13F information table with individual holdings is not included here.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 10:58 AM Learn about SEC filing dates

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F COVER PAGE

OMB APPROVAL

OMB Number:			3235-0006
Estimated average burden
hours per response:			23.8

Report for the Calendar Year or Quarter Ended: 06-30-2025

Check here if Amendment		Amendment Number:
This Amendment (Check only one.):		is a restatement.
		adds new holdings entries.

Institutional Investment Manager Filing this Report:
Name:	GILEAD SCIENCES, INC.
Address:	333 LAKESIDE DR
	FOSTER CITY, CA 94404
Form 13F File Number:	028-25078
CRD Number (if applicable):
SEC File Number (if applicable):

The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Person Signing this Report on Behalf of Reporting Manager:
Name:		Andrew D. Dickinson
Title:		Executive Vice President and Chief Financial Officer
Phone:		650-574-3000
Signature, Place, and Date of Signing:
/s/ Andrew D. Dickinson			FOSTER CITY, CA	08-14-2025
[Signature]			[City, State]	[Date]

Report Type (Check only one.):
X	13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)
	13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)
	13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).)

Form 13F Summary Page
	Report Summary:
	Number of Other Included Managers:		1
	Form 13F Information Table Entry Total:		14
	Form 13F Information Table Value Total:		1,280,204,668
			(round to nearest dollar)

List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report.
[If there are no entries in this list, state "NONE" and omit the column headings and list entries.]
	No.	Name	Form 13F File No.	CRD No. (if applicable)	SEC File No. (if applicable)	CIK
	1	Gilead Therapeutics A1 Unlimited Co	028-25083			0002055207